{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:27:18Z","timestamp":1791959238864,"version":"4.3.4"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bpg.2025.101994","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:09:58Z","timestamp":1741457398000},"page":"101994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine"],"prefix":"10.1016","volume":"77","author":[{"given":"L\u00e9a","family":"Sequier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Caillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10401","key":"10.1016\/j.bpg.2025.101994_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"issue":"10432","key":"10.1016\/j.bpg.2025.101994_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bpg.2025.101994_bib3","article-title":"Disease burden of patients with moderate to severe ulcerative colitis: a French multicenter real-life study (THEFAR)","volume":"S1590\u20138658","author":"Fumery","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"24","key":"10.1016\/j.bpg.2025.101994_bib4","first-page":"963","article-title":"Multidimensional patient-reported outcomes and quality of life at diagnosis of IBD: a population-based inception cohort study","volume":"S1542\u20133565","author":"Attauabi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.101994_bib5","article-title":"Disability in patients with inflammatory bowel disease: correlations with quality of life and patient's characteristics","volume":"2017","author":"Argyriou","year":"2017","journal-title":"Chin J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/apt.18231","article-title":"Review article: measuring disease severity in inflammatory bowel disease - beyond treat to target","volume":"60","author":"Swaminathan","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib7","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3748\/wjg.v25.i9.1142","article-title":"Conventional therapy for moderate to severe inflammatory bowel disease: a systematic literature review","volume":"25","author":"Dami\u00e3o","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.18194","article-title":"Systematic review: methotrexate-A poorly understood and underused medication in inflammatory bowel disease","volume":"60","author":"Sequier","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2025.101994_bib9","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","author":"Fudman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/ibd.21925","article-title":"Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation","volume":"18","author":"Baars","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cgh.2013.11.005","article-title":"Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease","volume":"12","author":"Bouguen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/ajg.2015.86","article-title":"Using a treat-to-target management strategy to improve the doctor-patient relationship in inflammatory bowel disease","volume":"110","author":"Rubin","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.101994_bib18","doi-asserted-by":"crossref","first-page":"S617","DOI":"10.1016\/j.jval.2019.09.1129","article-title":"PGI6 treatment failure and remission in moderate to severe ulcerative colitis (UC) and CROHN\u2019S disease (CD) in europe","volume":"22","author":"Achra","year":"2019","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib19","doi-asserted-by":"crossref","first-page":"otae026","DOI":"10.1093\/crocol\/otae026","article-title":"Real-world patterns and economic burden associated with treatment failure with advanced therapies in patients with moderate-to-severe ulcerative colitis","volume":"360","author":"Lee","year":"2024","journal-title":"Crohn\u2019s & Colitis"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/jcm11030829","article-title":"How to choose the biologic therapy in a bio-na\u00efve patient with inflammatory bowel disease","volume":"11","author":"Laredo","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib21","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1093\/rheumatology\/keac190","article-title":"Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib22","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1080\/03007995.2021.1981278","article-title":"Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis","volume":"37","author":"Gauthier","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis\u2014secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/apt.14466","article-title":"Comparison of infliximab with adalimumab in 827 biologic-na\u00efve patients with Crohn's disease: a population-based Danish cohort study","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl_1","key":"10.1016\/j.bpg.2025.101994_bib32","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/ecco-jcc\/jjx002.019","article-title":"OP020 Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease","volume":"11","author":"Gils","year":"2017","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ueg2.12563","article-title":"Therapeutic sequencing in inflammatory bowel disease: determining the optimal position of vedolizumab for long\u2010term Crohn's disease control using real\u2010world evidence","volume":"12","author":"Louis","year":"2024","journal-title":"United European Gastroenterology Journal"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib34","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib35","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"10342","key":"10.1016\/j.bpg.2025.101994_bib36","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib37","doi-asserted-by":"crossref","first-page":"i766","DOI":"10.1093\/ecco-jcc\/jjac190.0764","article-title":"P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry","volume":"17","author":"Calafat Sard","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib38","doi-asserted-by":"crossref","first-page":"i307","DOI":"10.1093\/ecco-jcc\/jjac190.0277","article-title":"P147 Trends in choice of first line biologic therapy for patients with Inflammatory Bowel Disease. An observational cohort study","volume":"17","author":"Fernando","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib39","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izac167","article-title":"Comparative effectiveness of ustekinumab and anti-TNF agent as first-line biological therapy in luminal Crohn's disease: a retrospective study from 2 referral centers","volume":"29","author":"Rivi\u00e8re","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib40","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/MEG.0000000000002411","article-title":"Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center","volume":"34","author":"Moens","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.bpg.2025.101994_bib41","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib42","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ecco-jcc\/jjad206","article-title":"Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn's disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies","volume":"18","author":"Colombel","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"Journal of Crohn\u2019s & Colitis."},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.dld.2016.02.012","article-title":"Effectiveness of anti-TNF\u03b1 drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF\u03b1 agent","volume":"48","author":"R-Grau","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib48","first-page":"606","article-title":"Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida registry","volume":"26","author":"Casanova","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"22","key":"10.1016\/j.bpg.2025.101994_bib49","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib50","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/ibd\/izy111","article-title":"Is the pharmacokinetic profile of a first anti-TNF predictive of the clinical outcome and pharmacokinetics of a second anti-TNF?","volume":"24","author":"Roblin","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/apt.16714","article-title":"Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor","volume":"55","author":"Parrot","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2025.101994_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102337","article-title":"Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-na\u00efve or anti-TNF-exposed Crohn's disease: a multicenter cohort study","author":"Yang","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12876-024-03403-8","article-title":"Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-na\u00efve and bio-experienced Crohn's disease patients: a retrospective multicenter study","volume":"24","author":"Na","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.bpg.2025.101994_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221144349","article-title":"Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study","volume":"15","author":"Bacsur","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib57","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1093\/ecco-jcc\/jjad212.0050","article-title":"DOP10 risankizumab versus ustekinumab for the achievement of endoscopic outcomes in patients with moderate-to-severe Crohn's disease: results from the phase 3b SEQUENCE trial","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.bpg.2025.101994_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn's disease: a Belgian multicentric cohort study","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib59","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.cgh.2023.11.033","article-title":"Risankizumab effectiveness and safety in Crohn's disease: real-world data from a large tertiary center","volume":"22","author":"Zinger","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ueg2.12547","article-title":"Difficult-to-treat inflammatory bowel disease: effectiveness and safety of 4th and 5th lines of treatment","volume":"12","author":"Caron","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib61","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2025.101994_bib63","article-title":"Mirikizumab sustained impact on fatigue in patients with moderately to severely active Crohn's disease in the phase 2 AMAG study","author":"Regueiro","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"10470","key":"10.1016\/j.bpg.2025.101994_bib64","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib65","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces Crohn's disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib66","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.cgh.2024.02.026","article-title":"Upadacitinib achieves clinical and endoscopic outcomes in Crohn's disease regardless of prior biologic exposure","volume":"22","author":"Peyrin-Biroulet","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib67","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn's disease","volume":"17","author":"Chugh","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib69","doi-asserted-by":"crossref","first-page":"otae060","DOI":"10.1093\/crocol\/otae060","article-title":"Upadacitinib in patients with difficult-to-treat Crohn's disease","volume":"360","author":"Bezzio","year":"2024","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.bpg.2025.101994_bib70","article-title":"PERSISTENCE, effectiveness, and safety of upadacitinib in CROHN\u2019S disease and ulcerative colitis in real life: results from a Spanish nationwide study (ureal study): upadacitinib for IBD","author":"Garc\u00eda","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib72","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies","volume":"109","author":"Frolkis","year":"2014","journal-title":"Official journal of the American College of Gastroenterology | ACG."},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib73","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/jcm13010119","article-title":"The management of postoperative recurrence in Crohn's disease","volume":"13","author":"Fasulo","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izab044","article-title":"Natural history and risk stratification of recurrent Crohn's disease after ileocolonic resection: a multicenter retrospective cohort study","volume":"28","author":"Joustra","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib76","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ecco-jcc\/jjac128","article-title":"Prophylactic medication for the prevention of endoscopic recurrence in Crohn's disease: a prospective study based on clinical risk stratification","volume":"17","author":"Arkenbosch","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib77","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00384-008-0542-9","article-title":"The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies","volume":"23","author":"Reese","year":"2008","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.gastro.2016.10.038","article-title":"American gastroenterological association institute guideline on the management of Crohn's disease after surgical resection","volume":"152","author":"Nguyen","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib79","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib80","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","article-title":"Risk prediction and comparative efficacy of anti-TNF vs thiopurines, for preventing postoperative recurrence in Crohn's disease: a pooled analysis of 6 trials","volume":"20","author":"Beelen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.dld.2014.11.005","article-title":"Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials","volume":"47","author":"Carla-Moreau","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib82","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ueg2.12068","article-title":"Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease","volume":"9","author":"Buisson","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib83","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/ecco-jcc\/jjac100","article-title":"Endoscopic postoperative recurrence in Crohn's disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world multicentre European study","volume":"16","author":"Yanai","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib84","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dld.2022.07.013","article-title":"Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: results from the ENEIDA registry","volume":"55","author":"Ma\u00f1osa","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2468-1253(24)00317-0","article-title":"Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"D'Haens","year":"2025","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib86","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.crohns.2012.02.012","article-title":"Adalimumab for the prevention and\/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study","volume":"6","author":"Papamichael","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib87","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000218","article-title":"Antitumor necrosis factor agents to treat endoscopic postoperative recurrence of Crohn's disease: a nationwide study with propensity-matched score analysis","volume":"11","author":"Ca\u00f1ete","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib88","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/jgh.16208","article-title":"Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease","volume":"38","author":"Macaluso","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.dld.2021.11.021","article-title":"Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"13","key":"10.1016\/j.bpg.2025.101994_bib90","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn's disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib91","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib92","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ecco-jcc\/jjx130","article-title":"Development of clinical prediction models for surgery and complications in Crohn's disease","volume":"12","author":"Guizzetti","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib93","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312673","article-title":"Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?","volume":"66","author":"Subramanian","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2025.101994_bib94","article-title":"Ileal and colonic Crohn's disease: does location makes a difference in therapy efficacy? Current Research","volume":"3","author":"Atreya","year":"2022","journal-title":"Pharmacol. Drug Discovery"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib95","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3390\/jcm11113045","article-title":"The optimal management of fistulizing Crohn's disease: evidence beyond randomized clinical trials","volume":"11","author":"Wetwittayakhlang","year":"2022","journal-title":"J Clin Med"},{"issue":"18","key":"10.1016\/j.bpg.2025.101994_bib96","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib97","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib98","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib99","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000702","article-title":"Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis","volume":"8","author":"Godoy Brewer","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib101","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.14309\/ajg.0000000000000810","article-title":"Ustekinumab for perianal Crohn's disease: the BioLAP multicenter study from the GETAID","volume":"115","author":"Chapuis-Biron","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib102","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn's disease: ENTERPRISE study","volume":"20","author":"Schwartz","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib104","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.15665","article-title":"Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients","volume":"51","author":"Chapuis-Biron","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib105","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.dld.2024.05.009","article-title":"Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: the HEAL study from GETECCU","volume":"56","author":"Casanova","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.101994_bib107","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn's disease: a post hoc analysis of 3 phase 3 trials","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib108","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/apt.16326","article-title":"Review article: investigation and management of internal fistulae in Crohn's disease","volume":"53","author":"Tjandra","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib109","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cgh.2019.05.027","article-title":"Efficacy and safety of tumor necrosis factor antagonists in treatment of internal fistulizing Crohn's disease","volume":"18","author":"Bouguen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.bpg.2025.101994_bib110","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/j.cgh.2023.01.013","article-title":"Adalimumab in biologic-na\u00efve patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the getaid","volume":"21","author":"Bouhnik","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib111","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ecco-jcc\/jjw016","article-title":"Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease","volume":"10","author":"Taxonera","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/MCG.0000000000000607","article-title":"A systematic review assessing medical treatment for rectovaginal and enterovesical fistulae in Crohn's disease","volume":"50","author":"Kaimakliotis","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib113","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.14946","article-title":"Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Th\u00e9rapeutique des Affections Inflammatoires du tube Digestif (GETAID)","volume":"48","author":"Le Baut","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib114","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2014.183","article-title":"Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID","volume":"109","author":"Amiot","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib115","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jgh.15330","article-title":"Efficacy of drug and endoscopic treatment of Crohn's disease strictures: a systematic review","volume":"36","author":"Schulberg","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib116","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib117","doi-asserted-by":"crossref","first-page":"i562","DOI":"10.1093\/ecco-jcc\/jjac190.0565","article-title":"P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study","volume":"17","author":"Buisson","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib118","doi-asserted-by":"crossref","first-page":"i1272","DOI":"10.1093\/ecco-jcc\/jjad212.0799","article-title":"P669 Efficacy of Ustekinumab-based integrated medicine therapy in patients with symptomatic stricturing Crohn's disease: a multicentre, prospective, observational cohort study","volume":"18","author":"Liu","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib119","article-title":"Tu1787 VEDOLIZUMAB AS A MEDICAL THERAPY FOR SYMPTOMATIC STRICTURING SMALL BOWEL CROHN\u2019S DISEASE - results from an international multicenter cohort study","volume":"164","author":"Ouali","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib121","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib122","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"American gastroenterological association clinical practice guideline on the medical management of moderate to severe luminal and fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"8167","key":"10.1016\/j.bpg.2025.101994_bib123","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib124","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National cooperative Crohn's disease study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"issue":"35","key":"10.1016\/j.bpg.2025.101994_bib125","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib126","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"13","key":"10.1016\/j.bpg.2025.101994_bib127","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib128","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.17616","article-title":"Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: a two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study","volume":"58","author":"Bokemeyer","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib131","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib132","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11096-018-0743-4","article-title":"Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis","volume":"40","author":"Trigo-Vicente","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"13","key":"10.1016\/j.bpg.2025.101994_bib133","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib134","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.bpg.2025.101994_bib135","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib136","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s10620-023-07956-8","article-title":"Comparative efficacy of infliximab versus tofacitinib for inducing remission in biologic naive ulcerative colitis: a propensity matched study","volume":"68","author":"Wong","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2025.101994_bib137","article-title":"O31 Tofacitinib versus vedolizumab among bio-na\u00efve patients with ulcerative colitis: a real-world propensity-weighted comparison","volume":"73","author":"Gros","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib138","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/apt.17570","article-title":"Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study","volume":"58","author":"Kochhar","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib139","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/jpm14101066","article-title":"Efficacy of second-line biological therapies in moderate to severe ulcerative colitis patients with prior failure of anti-tumor necrosis factor therapy: a multi-center study","volume":"14","author":"Na","year":"2024","journal-title":"J Personalized Med"},{"issue":"10S","key":"10.1016\/j.bpg.2025.101994_bib140","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.14309\/01.ajg.0000860228.75248.16","article-title":"S897 ustekinumab versus tofacitinib as second-line therapy for ulcerative colitis: a retrospective, observational study","volume":"117","author":"Galatowitsch","year":"2022","journal-title":"Official journal of the American College of Gastroenterology | ACG."},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib141","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1080\/00365521.2022.2095668","article-title":"Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study","volume":"57","author":"Meyer","year":"2022","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib142","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ecco-jcc\/jjae063","article-title":"Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"18","author":"Fumery","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib143","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"26","key":"10.1016\/j.bpg.2025.101994_bib144","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.bpg.2025.101994_bib145","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0452","article-title":"P322 compared efficacy of second-line treatments for ulcerative colitis after failure of vedolizumab in first-line treatment: a retrospective multicenter study","volume":"18","author":"Calmejane","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.bpg.2025.101994_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107108","article-title":"Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: systematic review and meta-analysis","volume":"202","author":"Zhang","year":"2024","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib147","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14712598.2024.2369189","article-title":"Management of proctitis in ulcerative colitis and the place of biological therapies","volume":"24","author":"De Deo","year":"2024","journal-title":"Expet Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib148","doi-asserted-by":"crossref","first-page":"769","DOI":"10.14309\/ajg.0000000000001685","article-title":"Urgency and its association with quality of life and clinical outcomes in patients with ulcerative colitis","volume":"117","author":"Sninsky","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis Mon"},{"issue":"10\u201311","key":"10.1016\/j.bpg.2025.101994_bib150","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1080\/00365521.2018.1524026","article-title":"Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression?","volume":"53","author":"Huguet","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib151","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/gutjnl-2021-324108","article-title":"Drug development for ulcerative proctitis: current concepts","volume":"70","author":"Caron","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib152","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2019.05.060","article-title":"Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis","volume":"18","author":"Pineton de Chambrun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib153","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/2050640620941345","article-title":"Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort","volume":"8","author":"Dubois","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib154","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cgh.2023.06.023","article-title":"Outcome of biological therapies and small molecules in ulcerative proctitis: a Belgian multicenter cohort study","volume":"22","author":"Lemmens","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjad169","article-title":"Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicentre cohort study from the getaid","volume":"18","author":"Uzzan","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib156","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.bpg.2025.101994_bib157","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib158","first-page":"652","article-title":"Predictors of aggressive inflammatory bowel disease","volume":"7","author":"Yarur","year":"2011","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib159","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib160","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib161","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib162","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib163","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a getaid multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib164","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib165","first-page":"173","article-title":"Rheumatological manifestations in inflammatory bowel disease","volume":"24","author":"Voulgari","year":"2011","journal-title":"Ann Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2025.101994_bib166","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib167","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease","volume":"104","author":"Barreiro-de-Acosta","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.bpg.2025.101994_bib168","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib169","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentre cohort study","volume":"16","author":"De Galan","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib171","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib172","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib174","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.bpg.2025.101994_bib176","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib177","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/jcm10020364","article-title":"Dermatological manifestations in inflammatory bowel diseases","volume":"10","author":"Antonelli","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib178","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","article-title":"Management of psoriasis in patients with inflammatory bowel disease: from the medical board of the national psoriasis foundation","volume":"78","author":"Whitlock","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.bpg.2025.101994_bib179","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib180","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9894","key":"10.1016\/j.bpg.2025.101994_bib181","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.bpg.2025.101994_bib182","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib183","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.bpg.2025.101994_bib184","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib185","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.MIB.0000442011.60285.68","article-title":"Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients","volume":"20","author":"Weizman","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib186","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/ecco-jcc\/jjaa078","article-title":"Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series","volume":"14","author":"Phillips","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib187","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2017.12.049","article-title":"Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review","volume":"78","author":"Afifi","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib188","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib189","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin manifestations of inflammatory bowel disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib190","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/ecco-jcc\/jjab079","article-title":"Systematic review: sweet syndrome associated with inflammatory bowel disease","volume":"15","author":"Sleiman","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib191","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaad.2016.08.031","article-title":"Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study","volume":"76","author":"Deckers","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib192","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjd.21066","article-title":"High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa","volume":"187","author":"Jiang","year":"2022","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib193","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib194","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib195","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/S2666-7568(22)00060-5","article-title":"Is it time to include older adults in inflammatory bowel disease trials? A call for action","volume":"3","author":"Vieujean","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib196","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/MIB.0000000000000738","article-title":"Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity?","volume":"22","author":"Jeuring","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib197","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12876-022-02620-3","article-title":"Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib198","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apt.14494","article-title":"Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study","volume":"47","author":"Ma\u00f1osa","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib199","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.bpg.2025.101994_bib201","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib202","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib203","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000001071","article-title":"Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease","volume":"23","author":"Navaneethan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib204","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.101994_bib205","article-title":"Indications and safety of newer IBD treatments in the older patient","volume":"1","author":"Clement","year":"2023","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib206","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14740338.2023.2247976","article-title":"An update on the safety of long-term vedolizumab use in inflammatory bowel disease","volume":"22","author":"Honap","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib207","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bpg.2025.101994_bib208","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib209","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"23","key":"10.1016\/j.bpg.2025.101994_bib210","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/jcm11236967","article-title":"Comparative safety of ustekinumab and vedolizumab in older patients with inflammatory bowel disease: a bicentric cohort study","volume":"11","author":"Burgevin","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpg.2025.101994_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(23)03533-3","article-title":"Tu1717 SAFETY PROFILE OF RISANKIZUMAB IN CROHN\u2019S DISEASE PATIENTS BY AGE: post-hoc analysis of the phase 3 advance, MOTIVATE, and FORTIFY studies","volume":"164","author":"Colombel","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib212","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti\u2010interleukin\u201023 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real\u2010world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib213","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib214","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib215","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNF\u03b1 therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Narula","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib216","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib218","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","article-title":"TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review","volume":"15","author":"Muller","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib219","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies","volume":"53","author":"Micic","year":"2019","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 3","key":"10.1016\/j.bpg.2025.101994_bib220","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2025.101994_bib221","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib222","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib223","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2025.101994_bib224","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9317","key":"10.1016\/j.bpg.2025.101994_bib225","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bpg.2025.101994_bib226","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib227","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.101994_bib228","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib229","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jcag\/gwad032","article-title":"Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease","volume":"7","author":"Wetwittayakhlang","year":"2023","journal-title":"J Can Assoc Gastroenterol."},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib230","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib231","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.bpg.2025.101994_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.03.039","article-title":"Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease","author":"Roblin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2025.101994_bib233","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/CEOR.S391413","article-title":"Systematic literature review of real-world evidence on dose escalation and treatment switching in ulcerative colitis","volume":"15","author":"Singh","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.bpg.2025.101994_bib234","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2025.101994_bib235","article-title":"Pos0809 switch or swap? Second targeted therapy choice in patients with spondyloarthritis: a cohort study within the French national health data system (snds)","volume":"83","author":"Richard","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_2","key":"10.1016\/j.bpg.2025.101994_bib236","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality","volume":"16","author":"Atreya","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib237","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cgh.2022.09.018","article-title":"I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease","volume":"21","author":"Peyrin-Biroulet","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2025.101994_bib238","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjw068","article-title":"Effectiveness research in inflammatory bowel disease: a necessity and a methodological challenge","volume":"10","author":"Salleron","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"10","key":"10.1016\/j.bpg.2025.101994_bib239","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ueg2.12336","article-title":"Treat\u2010to\u2010target and sequencing therapies in Crohn's disease","volume":"10","author":"Garcia","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"9613","key":"10.1016\/j.bpg.2025.101994_bib240","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bpg.2025.101994_bib241","doi-asserted-by":"crossref","first-page":"otab060","DOI":"10.1093\/crocol\/otab060","article-title":"Early start of infliximab in Crohn's disease increases rates of endoscopic remission and decreases stenosis formation: experiences from a single center cohort","volume":"360","author":"Schnitzler","year":"2021","journal-title":"Crohn\u2019s & Colitis"},{"issue":"7","key":"10.1016\/j.bpg.2025.101994_bib242","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in Crohn's disease but not in ulcerative colitis: systematic review and meta-analysis","volume":"30","author":"Law","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.bpg.2025.101994_bib243","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"10006","key":"10.1016\/j.bpg.2025.101994_bib244","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bpg.2025.101994_bib245","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:38:54Z","timestamp":1754293134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691825000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":245,"alternative-id":["S1521691825000216"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101994","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2025.101994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101994"}}